Need a specific person's email?
Browse Aeglea BioTherapeutics's employee directory (about 10 employees) and reveal verified emails free.
Aeglea BioTherapeutics's most common email format is FLast@aegleabio.com (ex. JDoe@aegleabio.com), used for 77% of aegleabio.com addresses. Aeglea BioTherapeutics uses 4 email patterns across 2 domains: aegleabio.com and aeglea.com. Percentages are the share of addresses within each domain.
| Format | Example | Share of aegleabio.com |
|---|---|---|
| FLast@aegleabio.comMost common | JDoe@aegleabio.com | |
| First.Last@aegleabio.com | John.Doe@aegleabio.com | |
| FirstLast@aegleabio.com | JohnDoe@aegleabio.com |
| Format | Example | Share of aeglea.com |
|---|---|---|
| FLast@aeglea.comMost common | JDoe@aeglea.com |
Browse Aeglea BioTherapeutics's employee directory (about 10 employees) and reveal verified emails free.
Biotechnology ResearchTexas, United States2-10 Employees
Aeglea BioTherapeutics is a biotechnology research company based in Austin, Texas. It has shifted its disease focus to inflammatory bowel disease following the acquisition of Spyre Therapeutics. Spyre Therapeutics brings capabilities in antibody engineering, rational therapeutic combinations, and precision immunology intended to enhance the effectiveness, safety, and convenience of IBD treatments. The move aligns Aeglea with Spyre’s program to pursue therapies for this disease area. The company targets patients with inflammatory bowel disease and the clinicians who treat them by pursuing more effective therapeutic options. In 2023, the organization announced a name change to Spyre Therapeutics and expanded its leadership to develop next-generation therapeutic combinations for inflammatory bowel disease.
Most common format
FLast@aegleabio.com
Example: JDoe@aegleabio.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.